NASDAQ:INGN Inogen (INGN) Stock Forecast, Price & News $5.21 +0.06 (+1.17%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$5.14▼$5.2950-Day Range$5.15▼$9.1152-Week Range$5.05▼$26.11Volume320,197 shsAverage Volume210,814 shsMarket Capitalization$120.82 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Inogen MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside168.7% Upside$14.00 Price TargetShort InterestHealthy2.13% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.26Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.35) to ($2.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector403rd out of 963 stocksSurgical Appliances & Supplies Industry10th out of 18 stocks 3.0 Analyst's Opinion Consensus RatingInogen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Inogen has a forecasted upside of 168.7% from its current price of $5.21.Amount of Analyst CoverageInogen has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.13% of the outstanding shares of Inogen have been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inogen has recently increased by 7.32%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInogen has received a 51.98% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Medical ventilators" product. See details.Environmental SustainabilityThe Environmental Impact score for Inogen is -1.12. Previous Next 1.8 News and Social Media Coverage News SentimentInogen has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inogen this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Inogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.64% of the stock of Inogen is held by insiders.Percentage Held by Institutions93.15% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($2.35) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inogen (NASDAQ:INGN) StockInogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; and related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Read More INGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INGN Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comInogen, Inc. (NASDAQ:INGN) Sees Significant Growth in Short InterestSeptember 19, 2023 | msn.comInogen (INGN) Completes Buyout Deal to Expand Product PortfolioSeptember 24, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 18, 2023 | markets.businessinsider.comInogen Closes Acquisition Of Physio-Assist SASSeptember 18, 2023 | finance.yahoo.comInogen Completes Acquisition of Physio-AssistSeptember 7, 2023 | markets.businessinsider.comInogen Names Mike Sergesketter As Interim CFO To Succeed Kristin CaltriderSeptember 7, 2023 | marketwatch.comInogen Chief Financial Officer Kristin Caltrider Resigns >INGNAugust 8, 2023 | msn.comJP Morgan Downgrades Inogen (INGN)September 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 8, 2023 | finance.yahoo.comInogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/YAugust 8, 2023 | finanznachrichten.deInogen Alliance: Chola Risk, Delta-Simons and Tonkin+Taylor Additions to the Leadership TeamAugust 8, 2023 | washingtonpost.comInogen: Q2 Earnings SnapshotAugust 8, 2023 | businesswire.comInogen Announces Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comHere's What Key Metrics Tell Us About Inogen (INGN) Q2 EarningsAugust 7, 2023 | finance.yahoo.comInogen Achieves Best In Class 8-Year Expected Service Life Portable Oxygen ConcentratorsAugust 4, 2023 | benzinga.comEarnings Preview For InogenJuly 20, 2023 | fool.comInogen (NASDAQ: INGN)July 17, 2023 | finance.yahoo.comInogen (INGN) Inks Buyout Agreement to Expand Product PortfolioJuly 14, 2023 | marketwatch.comInogen Shares Fall 15% After Needham Rating DowngradeJuly 14, 2023 | finance.yahoo.comInogen's (INGN) Preliminary Q2 Revenues Dampened by Lower SalesJuly 14, 2023 | benzinga.comDeclining Sales In Challenged Oxygen Market Weighs On Inogen's Margins, Analyst Downgrades StockJuly 13, 2023 | seekingalpha.comInogen: Still Struggling, But Very Cheap - Upgrading To BuyJuly 13, 2023 | finance.yahoo.comInogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-AssistJuly 12, 2023 | finance.yahoo.comInogen, Inc. (NASDAQ:INGN) is largely controlled by institutional shareholders who own 89% of the companyJune 28, 2023 | finance.yahoo.comNEXT Energy Technologies Appoints New Chief Executive OfficerJune 7, 2023 | finanznachrichten.deInogen Alliance: Understanding Environmental Contaminants: A Primer for BusinessesMay 16, 2023 | finance.yahoo.comWill the Current Downturn Affect Inogen (INGN)?See More Headlines Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Email Address INGN Company Calendar Last Earnings8/07/2023Today9/24/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN CUSIPN/A CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees1,026Year Founded2001Price Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$26.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+168.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,770,000.00 Net Margins-27.57% Pretax Margin-27.44% Return on Equity-14.95% Return on Assets-11.01% Debt Debt-to-Equity RatioN/A Current Ratio4.53 Quick Ratio4.02 Sales & Book Value Annual Sales$377.24 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value$12.98 per share Price / Book0.40Miscellaneous Outstanding Shares23,190,000Free Float23,046,000Market Cap$120.82 million OptionableOptionable Beta0.98 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Nabil Shabshab (Age 58)CEO, Pres & Director Comp: $943kMr. Michael K. Sergesketter (Age 63)Interim Exec. VP, Chief Financial Officer & Treasurer Comp: $227.53kDr. Stanislav Glezer M.D. (Age 50)MBA, Exec. VP & CTO Comp: $575.8kMr. Jason Somer (Age 55)Exec. VP, Gen. Counsel & Corp. Sec. Comp: $409.92kMs. Jennifer Yi BoyerExec. VP & Chief HR OfficerMr. Vijay PaliwalSr. VP of Enterprise EnablementMr. Matthew PigeonInvestor Relations OfficerMore ExecutivesKey CompetitorsJin Medical InternationalNASDAQ:ZJYLVicarious SurgicalNYSE:RBOTAnzu Special Acquisition Corp INASDAQ:ANZUMilestone ScientificNYSE:MLSSCollPlant BiotechnologiesNASDAQ:CLGNView All CompetitorsInstitutional OwnershipCalifornia State Teachers Retirement SystemSold 19,893 shares on 8/21/2023Ownership: 0.033%Nuveen Asset Management LLCSold 93,456 shares on 8/16/2023Ownership: 0.260%Wells Fargo & Company MNBought 3,485 shares on 8/15/2023Ownership: 0.039%Point72 Middle East FZEBought 2,549 shares on 8/15/2023Ownership: 0.016%Citadel Advisors LLCSold 2,700 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions INGN Stock - Frequently Asked Questions Should I buy or sell Inogen stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares. View INGN analyst ratings or view top-rated stocks. What is Inogen's stock price forecast for 2023? 4 Wall Street research analysts have issued 12-month price targets for Inogen's shares. Their INGN share price forecasts range from $8.00 to $26.00. On average, they expect the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 168.7% from the stock's current price. View analysts price targets for INGN or view top-rated stocks among Wall Street analysts. How have INGN shares performed in 2023? Inogen's stock was trading at $19.71 at the beginning of the year. Since then, INGN stock has decreased by 73.6% and is now trading at $5.21. View the best growth stocks for 2023 here. Are investors shorting Inogen? Inogen saw a increase in short interest in August. As of August 31st, there was short interest totaling 492,900 shares, an increase of 7.3% from the August 15th total of 459,300 shares. Based on an average trading volume of 400,500 shares, the short-interest ratio is currently 1.2 days. View Inogen's Short Interest. When is Inogen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our INGN earnings forecast. How were Inogen's earnings last quarter? Inogen, Inc. (NASDAQ:INGN) announced its earnings results on Monday, August, 7th. The medical technology company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.22. The medical technology company had revenue of $83.64 million for the quarter, compared to analyst estimates of $92.20 million. Inogen had a negative trailing twelve-month return on equity of 14.95% and a negative net margin of 27.57%. The business's revenue for the quarter was down 19.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.02) EPS. What guidance has Inogen issued on next quarter's earnings? Inogen updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $315.00 million-$320.00 million, compared to the consensus revenue estimate of $369.22 million. What is Scott Wilkinson's approval rating as Inogen's CEO? 70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX). What is Inogen's stock symbol? Inogen trades on the NASDAQ under the ticker symbol "INGN." Who are Inogen's major shareholders? Inogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.46%), Camber Capital Management LP (4.96%), Dimensional Fund Advisors LP (2.41%), Meros Investment Management LP (2.21%), Geode Capital Management LLC (2.02%) and State Street Corp (1.89%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger. View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inogen's stock price today? One share of INGN stock can currently be purchased for approximately $5.21. How much money does Inogen make? Inogen (NASDAQ:INGN) has a market capitalization of $120.82 million and generates $377.24 million in revenue each year. The medical technology company earns $-83,770,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. How many employees does Inogen have? The company employs 1,026 workers across the globe. How can I contact Inogen? Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net. This page (NASDAQ:INGN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.